OptimizeRx (NASDAQ:OPRX) & SS&C Technologies (NASDAQ:SSNC) Head-To-Head Review

OptimizeRx (NASDAQ:OPRX) and SS&C Technologies (NASDAQ:SSNC) are both computer and technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, valuation, earnings and risk.

Valuation and Earnings

This table compares OptimizeRx and SS&C Technologies”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OptimizeRx	$109.51 million	2.64	-$18.66 million	N/A	N/A
SS&C Technologies	$6.15 billion	3.42	$760.50 million	$3.37	25.59

SS&C Technologies has higher revenue and earnings than OptimizeRx.

Institutional and Insider Ownership

76.5% of OptimizeRx shares are owned by institutional investors. Comparatively, 96.9% of SS&C Technologies shares are owned by institutional investors. 5.6% of OptimizeRx shares are owned by company insiders. Comparatively, 16.4% of SS&C Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

OptimizeRx has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500. Comparatively, SS&C Technologies has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500.

Profitability

This table compares OptimizeRx and SS&C Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OptimizeRx	-9.42%	4.50%	3.12%
SS&C Technologies	13.86%	19.92%	6.98%

Analyst Recommendations

This is a breakdown of current recommendations for OptimizeRx and SS&C Technologies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OptimizeRx	1	2	7	1	2.73
SS&C Technologies	0	2	6	1	2.89

OptimizeRx presently has a consensus target price of $16.88, indicating a potential upside of 8.63%. SS&C Technologies has a consensus target price of $101.75, indicating a potential upside of 18.00%. Given SS&C Technologies’ stronger consensus rating and higher probable upside, analysts plainly believe SS&C Technologies is more favorable than OptimizeRx.

Summary

SS&C Technologies beats OptimizeRx on 11 of the 12 factors compared between the two stocks.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.

About SS&C Technologies

SS&C Technologies Holdings, Inc. engages in the development and provision of software solutions to the financial services and healthcare industries. It operates through the following geographical segments: United States, Europe, Middle East and Africa, Asia Pacific and Japan, Canada, and the Americas, excluding the United States and Canada. Its products include advent genesis, antares, asset allocators, AWD, axys, BANC mall, BRIX, DST vision, evare, lightning, and moxy. The company was founded by William Charles Stone in March 1986 and is headquartered in Windsor, CT.